Eyenovia’s phase 3 CHAPERONE study evaluating low-dose atropine delivered via the company’s Optejet dispenser is not meeting its primary endpoint of a less than 0.50 D progression in visual acuity over 3 years, according to a press release.
“We are disappointed that the [Data Review Committee (DRC)] determined that the CHAPERONE study does not appear to be meeting its primary efficacy endpoint,” Michael Rowe, Eyenovia’s CEO, said in the release. “We plan to terminate the study, review the data more thoroughly and evaluate next steps.”
According to the